Publication: Factors influencing treatment frequency of continuation ECT in schizophrenia
0
0
Issued Date
2001
Resource Type
File Type
application/pdf
ISSN
10950680
Other identifier(s)
2-s2.0-0034850934
Rights Holder(s)
มหาวิทยาลัยศรีนครินทรวิโรฒ
Bibliographic Citation
Journal of ECT. Vol 17, No.3 (2001), p.190-194
Suggested Citation
Chanpattana W., Chakrabhand M.L.S. Factors influencing treatment frequency of continuation ECT in schizophrenia. Journal of ECT. Vol 17, No.3 (2001), p.190-194. doi:10.1097/00124509-200109000-00008 Retrieved from: https://hdl.handle.net/20.500.14740/6854
Author(s)
Abstract
Although continuation and maintenance electroconvulsive therapy (C-ECT and M-ECT) have been used since 1943, no studies reported data that might help guide the selection of C-ECT frequency. This two-phase study was conducted in 32 chronic schizophrenic patients, with history of prior responsiveness to ECT to determine clinical variables associated with treatment frequency of C-ECT. After acute combination treatment with ECT and neuroleptics (Phase I), all patients received weekly ECT during the first 4 weeks of C-ECT (Phase II). They were then assigned to receive either weekly (n = 8) or biweekly (n = 24) ECT, depending on the history of their prior responsiveness to C-/M-ECT and their Brief Psychiatric Rating Scale (BPRS) scores. At the third month, patients with biweekly ECT were assigned to receive either biweekly (n = 17) or triweekly ECT (n = 7) following the same criteria. The duration of Phase II was 6 months. Onset of illness, numbers of admission, educational level, duration of trials of the previously failed neuroleptics, BPRS scores, and percentage of reductions in BPRS scores at the end of Phase I, Global Assessment of Functioning (GAF) scores at the end of Phase I, Mini-Mental State Exam (MMSE) scores at Phase I entry and Phase I end, and GAF and MMSE scores during the first month of Phase II showed a differentiation between patients having weekly treatment versus biweekly treatment. Whereas a history of previously failed flupenthixol treatment, dosage of flupenthixol used in this study, and MMSE scores at the end of Phase I and during the first month of Phase II showed a differentiation between patients having biweekly C-ECT versus triweekly C-ECT. Our results suggest that the better the prognostic factors for each patient, the longer the frequency of C-ECT.
Subject(s)
Flupentixol
Neuroleptic agent
Adult
Article
Chronic disease
Clinical article
Controlled study
Electroconvulsive therapy
Female
Functional assessment
Human
Male
Prognosis
Rating scale
Schizophrenia
Treatment outcome
Treatment planning
Adult
Chronic Disease
Electroconvulsive Therapy
Female
Humans
Male
Prognosis
Recurrence
Risk Factors
Schizophrenia
Time Factors
Treatment Outcome
Neuroleptic agent
Adult
Article
Chronic disease
Clinical article
Controlled study
Electroconvulsive therapy
Female
Functional assessment
Human
Male
Prognosis
Rating scale
Schizophrenia
Treatment outcome
Treatment planning
Adult
Chronic Disease
Electroconvulsive Therapy
Female
Humans
Male
Prognosis
Recurrence
Risk Factors
Schizophrenia
Time Factors
Treatment Outcome